Abstract
Accelerated SARS-CoV-2 evolution under selective pressure by massive deployment of neutralizing antibody-based therapeutics is a concern with potentially severe implications for public health. We review here reports of documented immune escape after treatment with monoclonal antibodies and COVID19 convalescent plasma (CCP). While the former is mainly associated with specific single amino acid mutations at residues within the receptor-binding domain (e.g., E484K/Q, Q493R, and S494P), the few cases of immune evasion after CCP were associated with recurrent deletions within the N-terminal domain of Spike protein (e.g, ΔHV69-70, ΔLGVY141-144 and ΔAL243-244). Continuous genomic monitoring of non-responders is needed to better understand immune escape frequencies and fitness of emerging variants.
Introduction
SARS-CoV-2 Spike protein is the target of neutralizing antibody (nAb)-based therapeutics. Control of the COVID19 pandemic is being hampered by continued evolution of SARS-CoV-2, which includes mutations in the Spike protein that can affect immunogenicity and antibody-mediated neutralization. Evolutionary modeling suggests that SARS-CoV-2 strains harboring 1-2 deleterious mutations naturally exist, and their frequency increases steeply under positive selection by monoclonal antibodies (mAb) and vaccines [1]. In 2% of COVID cases, SARS-CoV-2 variants with multiple mutations occur, including in the Spike glycoprotein, which can become the dominant strains in as little as one month of persistent in-patient virus replication [2]. While mutations can occur as a natural phenomenon of SARS-CoV-2 RNA replication and editing, the pace of mutagen emergence can also be affected by small-chemical antivirals (e.g. remdesivir [3] or molnupiravir [4]). Since antibody-based therapies targeting the spike protein would also put selective pressure on SARS-CoV-2, it is reasonable to assume that widespread deployment of nAb-based therapeutics could accelerate Spike immune escape by selecting for variants resist neutralization.
Mutations that confer in vitro resistance to therapeutic anti-Spike mAbs have been characterized with various methods, and are informative about treatment-emergent immune escape. Deep mutational scanning (DMS) predicts protein expression, ACE2 binding, and mAb binding [5]. The method was first deployed with yeast display libraries [6], then evolved to phage display libraries (https://jbloomlab.github.io/SARS-CoV-2-RBD_MAP_clinical_Abs/) [44] and finally mammalian cell surface display [7]. nAb binding is common within the fusion peptide and in the linker region before heptad repeat (HR) region 2. The complete escape maps forecast SARS-CoV-2 mutants emerging during treatment with mAbs, and allow the design of escape-resistant nAb cocktails. Complete map of SARS-CoV-2 RBD mutations that escape bamlanivimab and its cocktail with etesevimab have been generated [8, 9].
Although DMS was also applied to polyclonal antibodies in COVID19 convalescent plasma (CCP) [10], the problem is much more complex such that it is almost impossible to identify escape mutations in CCP or vaccinee elicited sera, given the huge heterogeneity in antibody response among CCP donors and vaccinees, respectively. In vitro, continuous passaging of SARS-CoV-2 in the presence of a CCP unit with nAb titer >1:104 led to ΔF140 Spike mutation at day 45, followed by E484K at day 73, and an insertion in the N-terminal domain (NTD): these accumulating mutations led to complete immune escape [11]. Similarly, K417N, E484K, and N501Y mutations were selected when pseudotyped SARS-CoV-2 was cultured in the presence of vaccine-elicited mAbs [12]. Although some have speculated that the large-scale use of CCP for COVID-19 could have played a role in the emergence of variants there is no evidence for such an effect and the most likely explanation for regular emergence of variants has been huge number of affected individuals since each infection case provides a natural opportunity for variant creation [13].
In vivo, while intra-host SARS-CoV-2 mutation development is typically very low [14], faster mutation rates (referred as “accelerated evolution”) have been found in longitudinal studies of immunodeficient patients who had persistent SARS-CoV-2 infections for several months and were treated with nAb-based therapeutics. In this study we analyze and compare the available mutational data from SARS-CoV-2 under in vitro and in vivo selection and demonstrate that mAb and polyclonal (CCP) therapies elicit different types of mutational patterns.
Methods
We mined PubMed (which also indexes the bioRxiv and medrXiv preprint servers) for keywords related to COVID19 (“COVID19”, “SARS-CoV-2”), immune escape (“immune escape”, “treatment-emergent resistance”) and nAb-based therapeutics (“convalescent plasma”, “casirivimab”, “imdevimab”, “bamlanivimab”, etesevimab”, “sotrovimab, “regdanvimab”) both in vitro and in vivo. Clinical cases were annotated for eventual underlying immune deficiency, concurrent treatments and outcome. Figure 1 reports the study selection process according to PRISMA 2020 guidelines [15].
The 3D structural coordinates of the full Spike protein (PDBID 6VXX; residues 27-1252) [16] and the receptor binding domain (PBDID 7BWJ; residues 319-529) [17], solved by cryo-electron microscopy and X-ray crystallography, respectively, were used to map mutational positions of interest. Mapping on the full Spike was used to illustrate the diverse set of mutations throughout the Spike glycoprotein, while the mutations localized to the RBD were illustrated using the more complete structural model obtained through crystallography. The mutations identified in each condition of in vivo or in vitro selection were tabulated and highlighted on the structures using color coding with PyMOL [18].
Results
Our literature search revealed 32 papers that were then manually inspected to determine whether they included relevant information that was then retrieved, evaluated and organized into Tables.
Table 1 summarizes Spike protein mutations associated with in vitro resistance to mAbs targeting this protein. These mutations were used to filter clinical case reports of treatment resistance for evidence of immune escape (Table 2).
Table 3 summarizes Spike mutations found in clinical cases after CCP treatment, where, immune escape can be hypothesized to have occurred based on treatment failure, with the caveat that there is no definitive proof of immune escape due to heterogeneity of the (uncharacterized) polyclonal response.
Table 4 summarizes data from reports within-host clonal evolution within immunosuppressed patients not treated with nAb-based therapeutics.
Figure 2 depicts the Spike RBD mutations of concern for mAb binding detected in vitro and in vivo and the Spike mutations detected after CCP usage.
Discussion
Escape from nAb based therapeutics provides a crucial demonstration that these immune therapies target protective antigens, which the pathogen actively evades. Hence, the emergence of neutralizing-resistant variants in individuals receiving mAb and CCP provides powerful evidence for their antiviral activity. This evidence is independent of reduction in viral load, which has been reported with mAbs given early in disease but have been an inconsistent finding in randomized controlled trials (RCT) of CCP for COVID-19 [51].
Getting frequencies for this phenomenon from case series is not possible due to the high risk of selection biases, which would yield unrealistically high frequencies. In contrast, RCTs with their control groups are the suggested reference. With bamlanivimab, there was no emergence of resistance in the patients receiving 7000 mg, but resistance was reported in patients receiving 700 mg (8 cases: 7% vs 0% with placebo) [22]. Putative treatment-emergent bamlanivimab-resistant variants were detected in 7.1% of patients (7/98) in the 700 mg group, 9.8% of patients (10/102) in the 2800 mg group, 11.3% of patients (11/97) in the 7000 mg group, 1% of patients (1/102) in the bamlanivimab and etesevimab combination group, and in 4.8% of patients (7/145) in the placebo group. The bamlanivimab monotherapy groups had a higher frequency of patients in whom a variant was detected at more than 1 time point during the viral time course (4.1% for the 700 mg group, 5.9% for the 2800 mg group, and 7.2% for the 7000 mg group) than the placebo group or the bamlanivimab and etesevimab combination group (both 0%) [29]. Apart from registration trials, the largest case series to date evaluated the impact of mAbs on the nasopharyngeal (NP) viral load and virus quasi-species of mAb-treated patients using single-molecule real-time sequencing after bamlanivimab alone (4 patients), bamlanivimab/etesevimab (23 patients) and casirivimab/Imdevimab (5 patients) [32]. To date a single case of immune escape has been reported for the non-overlapping REGN-COV2 cocktail, and accordingly hamster models and clinical trials showed no emergence of variants [52]. Since mAb therapy by definition targets only a single epitope within the RBD, it is unsurprising that escape mutations observed after in vitro and in vivo selection by these mAbs were single amino acid substitutions localized almost exclusively to the RBD (Figure 2, bottom panel; Tables 1 and 2), as expected from in vitro studies with single mAb, but largely prevented by non-overlapping mAb cocktails [53].
In contrast to mAb therapeutics, immune escape under CCP has not been investigated in RCTs. Hence evidences exclusively stem from case series and case reports [54], and is further complicated by exposure to multiple CCP units from different donors, each one having a polyclonal response at differing titers and affinity. Unfortunately nAb titers were very rarely determined or reported, precluding correlations between emergence of resistance and subneutralizing CCP doses. Overall, it seems that escape variants from CCP selection have not been reported as commonly nor emerged as fast. E.g., none out of 8 recipients of HSCT or CART who were treated with CCP and tested SARS-CoV-2-positive for 2 months showed significant mutations compared to the original strain [55]. Review of the Spike protein changes associated with resistance after CCP therapy reveal that most of them had in-frame amino acid deletions in a flexible region that is partially solvent exposed and forms a β strand: plasticity may contribute to the structural permissibility of the identified deletions. The NTD is a flexible region that can be affected by immune escape via either insertions (causing additional glycosylation sites [11]) or recurrently deleted regions (RDR) ΔHV69–70 (RDR1), ΔLGVY141–144 and ΔD146 (RDR2), ΔI210 (RDR3) and ΔAL243–244 (RDR4) [56] : RDR1, RDR2 and RDR4 correspond to NTD loops N2, N3 and N5, whereas RDR3 falls between N4 and N5.
Deletions of amino acids from a protein structure generally results in greater structural changes than single amino acid changes, since these reduce the size of the protein and can trigger changes that propagate through the whole structure. Furthermore, the mechanism for the emergence of deletion variants appears to be very different from the single amino acid changes that are frequent from error-prone RNA replication and could involve deletions from RNA editing. Since CCP targets a large number of epitopes in the Spike protein while mAbs target a single epitope these molecular differences parallel what is expected from their respective selection pressures in the sense that escape from polyclonal preparations requires larger antigenic structural changes than escape from mAbs. In contrast to escape mutations selected for by mAb therapy, CCP selection yields point mutations throughout the Spike protein. This reflects the vast antigenic surface area covered by the polyclonal antibodies within CCP. Escape mutations would be theoretically selected for on the basis of the most potent antibodies present in a particular CCP unit, which may vary markedly from donor to donor, which could explain the generally divergent evolution of SARS-CoV-2 in the presence of CCP. However, residues 141-144 and 243-244 are the sites of mutations or deletions in several cases, indicating these sites may offer effective escape from CCP derived from many donors, possibly by triggering a large-scale conformational rearrangement, as discussed above. As RBD binding antibodies are often neutralizing via ACE2 receptor occlusion, it is interesting that only 23% of CCP case studies identified escape mutations within the RBD (Figure 2, top panel; Table 3). This suggests that antibody binding to other sites on the Spike protein may have additional mechanisms of neutralization (i.e., by preventing conformational change after ACE2 engagement), or that additional antibody mediated immune responses (e.g., ADCC) are equally important as direct neutralization to the antiviral response to SARS-CoV-2.
Nothing can be inferred about the fitness of an emerging mutant in the absence of selective pressure, but it is of interest that one variant with the E484K mutant that emerged after bamlanivimab therapy was able to infect multiple household contacts [27]. In vitro, several mutants showed similar infectivity to wild type strain but resistance to different CCP donors [36]. In one instance of immune escape associated with CCP, a variant with D796H mutation manifested modestly reduced sensitivity to neutralization by CCP that was associated with reduced infectivity, which was only partly compensated by ΔHV69-70 [36]. Even if immune escape in registration trials has been a rare phenomenon, it should be considered that in the real-world practice mAbs targeting the SARS-CoV-2 Spike protein are being reserved for use in high-risk (immunocompromised) patients. Considering the huge size of a pandemic, the likelihood of immune escape becomes relevant, raising the possibility that rare variants with enhanced fitness could drive next pandemic waves. Notably, several mutations have recurred in VOC and VOIs (e.g. E484K found in Beta and Gamma, E484Q found in Delta, or ΔLHR244-246 [41] found in VOI lambda), raising the possibility that such variants emerged during treatment of patients (iatrogenic variants), but such inference will likely remain very hard to prove. E406W mutation has never been reported in GISAID, and other E406 mutations remain exceedingly rare (worldwide 318 cases of E406Q, 41 cases of E406D, and 2 cases each from USA for E406G, E406A, E406K, and 1 case of E406V out of 4,410,787 sequences deposited in GISAID as of October 25, 2021). Similarly, Q493R has only been reported in 244 sequences and Q493K in 138 sequences (source: Outbreak.info). Lack of fixation of those mutation facilitates the imputation that these require mAb selective pressure and/or effective infection control techniques in the care of those patients prevented spill over to the general population.
Within host variation (so-called “quasi-species swarm”) is a natural phenomenon which has been reported for SARS-CoV-2 in immunocompetent patients and ultimately facilitates persistence of infection. Among 33 patients having positive NPS PCR for an average of 18 days, Voloch et al observed a distinguishing pattern of mutations over the course of the infection mainly driven by increasing A→U and decreasing G→A signatures, including Spike mutations (V362L, T553I, H655Y, A688V, S691F, S884F, V1176F). G→A mutations are driven by RNA-editing enzyme activities typical of innate immunity [57]. Nevertheless, several covariates can facilitate immune escape.
Immunosuppression has been postulated to be an accelerator for viral evolution. Actually, Table 4 shows that very few case reports have detailed intraclonal (within-host) evolution in patients receiving immunosuppressive treatment, and, in the absence of nAb-based therapeutics, Spike mutations rarely occurred [55].
On the other hand, co-administered small chemical antivirals can be mutagenic per se. Remdesivir can adopt both amino and imino tautomeric conformations to base-pair with RNA bases [58]. Both amino-remdesivir:G and imino-remdesivir:C pairs could be quite mutagenic. Serial in vitro passages of SARS-CoV-2Engl2 in cell culture media supplemented with remdesivir selected for drug-resistant viral populations. Remdesivir triggers the selection of SARS-CoV-2 variant with a E802D mutation in the RdRp sufficient to confer decreased sensitivity to remdesivir without affecting viral fitness. The analysis of more than 200,000 sequences also revealed the occurrence of 22 mutations in Spike, including changes in amino acids E484 and N501 corresponding to mutations identified in Alpha and Beta [59]. It has been hence been proposed than nAb-based therapeutics could amplify mutations induced by remdesivir [3]. In this regard, Table 4 shows that many of the mAb- or CCP-associated mutations emerged in individuals who were or had been treated with remdesivir (but neither mAbs nor CCP), consistent with the notion that antiviral therapy could potentiate the emergence of antibody-resistance mutations.
Conclusion
In summary, our survey of the available mutational data show that escape variants associated with mAb and CCP therapy manifest different type of mutations. For mAbs most mutations are single amino acid replacements in the RBD domain, while most variants eliciting in patients treated with CCP exhibited amino acid deletions. In fact, it is noteworthy that RBD mutations were relatively rare in CCP escape variants. Although the numbers are relatively small, which suggests cation in making generalizations, this dichotomy in geography of mAb and CCP mutations could reflect the fact that mAbs target a single epitope where the mAb-antigen interaction can be significantly altered by single amino acid changes while CCP targets many epitopes and has several mechanisms of action, such that evading polyclonal antibody immunity is likely to require much larger Spike protein structural changes. Despite the relatively small set of variants for which there is molecular data available, the large variation of molecular solutions that allow SARS-CoV-2 to escape antibody-mediated protection is striking and suggest the need for continued vigilance in genomic surveillance, especially in cases refractory to therapy.
We declare we don’t have any conflict of interest related to this manuscript.
Data Availability
All data produced in the present work are contained in the manuscript
Footnotes
fabrizio.maggi63{at}gmail.com
massimo.franchini{at}asst-mantova.it
acasade1{at}jhu.edu; smcconn8{at}jhu.edu
Abbreviations
- nAb
- neutralizing antibodies
- CCP
- COVID19 convalescent plasma
- PSM
- propensity score-matched
- RCT
- randomized controlled trials.